Serum sclerostin is an independent predictor of mortality in hemodialysis patients

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorGONCALVES, Flavia Leticia Carvalho
dc.contributor.authorELIAS, Rosilene M.
dc.contributor.authorREIS, Luciene M. dos
dc.contributor.authorGRACIOLLI, Fabiana G.
dc.contributor.authorZAMPIERI, Fernando Godinho
dc.contributor.authorOLIVEIRA, Rodrigo B.
dc.contributor.authorJORGETTI, Vanda
dc.contributor.authorMOYSES, Rosa M. A.
dc.date.accessioned2015-04-22T22:20:33Z
dc.date.available2015-04-22T22:20:33Z
dc.date.issued2014
dc.description.abstractBackground: Sclerostin (Scl) has recently emerged as a novel marker of bone remodeling and vascular calcification. However, whether high circulating Scl is also a risk factor for death is not well established. The purpose of this study was to test whether serum Scl would be associated with mortality. Methods: we measured serum Scl in a hemodialysis patients' cohort, which was followed during a ten-year period. Competing risk regression models were applied, as during the follow-up, patients were exposed to both events kidney transplant and death. Results: Ninety-one patients aged 42.3 +/- 18.8 years (55% of male gender, 15% of diabetes) were included. During the follow-up, 32 patients underwent kidney transplant and 26 patients died. Non-survivals presented higher FGF23, higher Scl and lower creatinine. There was an association between all-cause mortality and higher Scl (HR = 2.2), higher age (HR = 1.04) and presence of diabetes (HR = 2.27), by competing risk analyses. Even including potential markers of mortality, as creatinine, FGF 23, and gender, Scl, age and diabetes remained significantly related to higher mortality. Conclusion: Serum Scl is an independent predictor of mortality in dialysis patients. However, whether clinical interventions to modulate Scl would be able to improve these patients survival needs to be determined.
dc.description.indexMEDLINE
dc.description.sponsorshipCNPQ, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [304249/2013-0]
dc.identifier.citationBMC NEPHROLOGY, v.15, article ID 190, 7p, 2014
dc.identifier.doi10.1186/1471-2369-15-190
dc.identifier.issn1471-2369
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/9141
dc.language.isoeng
dc.publisherBIOMED CENTRAL LTD
dc.relation.ispartofBMC Nephrology
dc.rightsopenAccess
dc.rights.holderCopyright BIOMED CENTRAL LTD
dc.subjectSclerostin
dc.subjectChronic renal failure
dc.subjectCKD-MBD
dc.subjectHemodialysis
dc.subjectMortality risk
dc.subject.otherbone-marrow transplants
dc.subject.otherrenal osteodystrophy
dc.subject.otherstatistical-methods
dc.subject.othermineral metabolism
dc.subject.othercompeting risk
dc.subject.otherregression
dc.subject.otherosteocyte
dc.subject.otherdialysis
dc.subject.otheroutcomes
dc.subject.otherdisease
dc.subject.wosUrology & Nephrology
dc.titleSerum sclerostin is an independent predictor of mortality in hemodialysis patients
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus71
hcfmusp.contributor.author-fmusphcFLAVIA LETICIA CARVALHO GONCALVES
hcfmusp.contributor.author-fmusphcROSILENE MOTTA ELIAS
hcfmusp.contributor.author-fmusphcLUCIENE MACHADO DOS REIS
hcfmusp.contributor.author-fmusphcFABIANA GIORGETI GRACIOLLI
hcfmusp.contributor.author-fmusphcFERNANDO GODINHO ZAMPIERI
hcfmusp.contributor.author-fmusphcRODRIGO BUENO DE OLIVEIRA
hcfmusp.contributor.author-fmusphcVANDA JORGETTI
hcfmusp.contributor.author-fmusphcROSA MARIA AFFONSO MOYSES
hcfmusp.description.articlenumber190
hcfmusp.description.volume15
hcfmusp.origemWOS
hcfmusp.origem.pubmed25465028
hcfmusp.origem.scopus2-s2.0-84923860948
hcfmusp.origem.wosWOS:000347358300001
hcfmusp.publisher.cityLONDON
hcfmusp.publisher.countryENGLAND
hcfmusp.relation.referenceBaron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
hcfmusp.relation.referenceBlock GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
hcfmusp.relation.referenceBonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
hcfmusp.relation.referenceBrandenburg VM, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-219
hcfmusp.relation.referenceCejka D, 2011, CLIN J AM SOC NEPHRO, V6, P877, DOI 10.2215/CJN.06550810
hcfmusp.relation.referenceCosta AG, 2014, OSTEOPOROSIS INT, V25, P1547, DOI 10.1007/s00198-014-2635-3
hcfmusp.relation.referencede Oliveira RB, 2013, NEPHROL DIAL TRANSPL, V28, P2510, DOI 10.1093/ndt/gft234
hcfmusp.relation.referenceFerreira JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079721
hcfmusp.relation.referenceFine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
hcfmusp.relation.referenceGooi JH, 2010, BONE, V46, P1486, DOI 10.1016/j.bone.2010.02.018
hcfmusp.relation.referenceGutierrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
hcfmusp.relation.referenceKanbay M, 2012, INT UROL NEPHROL, V44, P1169, DOI 10.1007/s11255-011-0076-x
hcfmusp.relation.referenceKidney Disease: Improving Global Outcomes CKDMBDWG, 2009, KIDNEY INT S, V113, pS1
hcfmusp.relation.referenceKlein JP, 2001, BONE MARROW TRANSPL, V28, P909, DOI 10.1038/sj.bmt.1703260
hcfmusp.relation.referenceKlein JP, 2001, BONE MARROW TRANSPL, V28, P1001, DOI 10.1038/sj.bmt.1703271
hcfmusp.relation.referenceKramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428-09
hcfmusp.relation.referenceMoe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
hcfmusp.relation.referenceSabbagh Y, 2012, J BONE MINER RES, V27, P1757, DOI 10.1002/jbmr.1630
hcfmusp.relation.referenceScrucca L, 2010, BONE MARROW TRANSPL, V45, P1388, DOI 10.1038/bmt.2009.359
hcfmusp.relation.referenceTeixeira L, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-110
hcfmusp.relation.referenceTentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
hcfmusp.relation.referenceVerduijn M, 2011, NEPHROL DIAL TRANSPL, V26, P56, DOI 10.1093/ndt/gfq661
hcfmusp.relation.referenceViaene L, 2013, NEPHROL DIAL TRANSPL, V28, P3024, DOI 10.1093/ndt/gft039
hcfmusp.relation.referenceVittinghoff E, 2007, AM J EPIDEMIOL, V165, P710, DOI 10.1093/aje/kwk052
hcfmusp.relation.referenceWesseling-Perry K, 2013, BONE, V54, P222, DOI 10.1016/j.bone.2012.10.008
hcfmusp.relation.referenceZhu DX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019595
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication9d89b71e-fb85-42bc-a0f1-ab2a49268c15
relation.isAuthorOfPublication96f51de1-5516-4c3f-8bbe-e187ad50e121
relation.isAuthorOfPublication70ba19b2-5cd8-4534-964c-15b0d4466682
relation.isAuthorOfPublicationb31326d9-0030-4f17-8344-342f2c401e86
relation.isAuthorOfPublication8246c86b-7b2c-4755-ad3b-c0b3d253b4ed
relation.isAuthorOfPublicationde643204-5f2c-403d-ba97-a847cf0a4cd5
relation.isAuthorOfPublication43722089-d1f9-4d2c-98df-79d676fb6a5a
relation.isAuthorOfPublication75bfa547-8f40-42b9-9d98-3bafa53bb29b
relation.isAuthorOfPublication.latestForDiscovery9d89b71e-fb85-42bc-a0f1-ab2a49268c15
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_GONCALVES_Serum_sclerostin_is_an_independent_predictor_of_mortality_2014.PDF
Tamanho:
209.06 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/16
Artigos e Materiais de Revistas Científicas - ODS/03